A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults

Paola Lucidi, Marco Lauteri, Stefano Laureti, Roberta Celleno, Stefania Santoni, Elena Volpi, Gabriella Angeletti, Fausto Santeusanio, Pierpaolo De Feo

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

This study was designed to establish the lower dose of effective GH replacement therapy in severe GH-deficient (GHD) adults. Whole body protein and lipid kinetics were determined in six GHD men in the basal state (B) and after 1 week of treatment with placebo (PL) or 3.3 (GH3.3) or 2 (GH2) μg/kg·day recombinant human GH (rhGH). The rates of whole body proteolysis, oxidation, and synthesis were estimated by infusing [1-13C]leucine (prime, 1 mg/kg; infusion rate, 1 mg/kg·h); those of lipolysis (measured in four of the six patients) were estimated by infusing [1,1,2,3,3-D5]glycerol (prime, 1.8 μmol/kg; infusion rate, 0.06 μmol/kg·min). Serum insulin-like growth factor I (IGF-I) concentrations (picograms per mL; mean ± SE) similarly increased from the basal level (39 ± 7) after 3.3 (108 ± 18) or 2 (109 ± 24) μg/kg·day rhGH (P < 0.001 vs. basal), whereas they did not change with placebo (41 ± 8). Leucine Ra was unaffected by the treatments. GH3.3 reduced by 30% the rate of leucine oxidation (P = 0.0069 vs. basal) and increased by 11% nonoxidative leucine disposal (P = 0.0095 vs. basal) and by 21% glycerol Ra (0.0035 vs. basal); GH2 and placebo had no significant effect. In conclusion, 1) at least 3.3 μg/kg·day rhGH are required to increase whole body protein synthesis and lipolysis in male GHD adults; 2) 2 μg/kg·day rhGH normalize serum IGF-I concentrations, but do not modify protein and lipid metabolism; and 3) a normal serum IGF-I concentration does not guarantee that rhGH treatment is also effective on intermediate metabolism.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume83
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Leucine
Growth Hormone
Insulin-Like Growth Factor I
Lipids
Kinetics
Lipolysis
Placebos
Glycerol
Proteins
Serum
Proteolysis
Oxidation
Human Growth Hormone
Hormone Replacement Therapy
Lipid Metabolism
Metabolism
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. / Lucidi, Paola; Lauteri, Marco; Laureti, Stefano; Celleno, Roberta; Santoni, Stefania; Volpi, Elena; Angeletti, Gabriella; Santeusanio, Fausto; De Feo, Pierpaolo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 2, 1998, p. 353-357.

Research output: Contribution to journalArticle

Lucidi, Paola ; Lauteri, Marco ; Laureti, Stefano ; Celleno, Roberta ; Santoni, Stefania ; Volpi, Elena ; Angeletti, Gabriella ; Santeusanio, Fausto ; De Feo, Pierpaolo. / A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. In: Journal of Clinical Endocrinology and Metabolism. 1998 ; Vol. 83, No. 2. pp. 353-357.
@article{cbc3bca91dbd469ca8d59d1bd9411aa9,
title = "A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults",
abstract = "This study was designed to establish the lower dose of effective GH replacement therapy in severe GH-deficient (GHD) adults. Whole body protein and lipid kinetics were determined in six GHD men in the basal state (B) and after 1 week of treatment with placebo (PL) or 3.3 (GH3.3) or 2 (GH2) μg/kg·day recombinant human GH (rhGH). The rates of whole body proteolysis, oxidation, and synthesis were estimated by infusing [1-13C]leucine (prime, 1 mg/kg; infusion rate, 1 mg/kg·h); those of lipolysis (measured in four of the six patients) were estimated by infusing [1,1,2,3,3-D5]glycerol (prime, 1.8 μmol/kg; infusion rate, 0.06 μmol/kg·min). Serum insulin-like growth factor I (IGF-I) concentrations (picograms per mL; mean ± SE) similarly increased from the basal level (39 ± 7) after 3.3 (108 ± 18) or 2 (109 ± 24) μg/kg·day rhGH (P < 0.001 vs. basal), whereas they did not change with placebo (41 ± 8). Leucine Ra was unaffected by the treatments. GH3.3 reduced by 30{\%} the rate of leucine oxidation (P = 0.0069 vs. basal) and increased by 11{\%} nonoxidative leucine disposal (P = 0.0095 vs. basal) and by 21{\%} glycerol Ra (0.0035 vs. basal); GH2 and placebo had no significant effect. In conclusion, 1) at least 3.3 μg/kg·day rhGH are required to increase whole body protein synthesis and lipolysis in male GHD adults; 2) 2 μg/kg·day rhGH normalize serum IGF-I concentrations, but do not modify protein and lipid metabolism; and 3) a normal serum IGF-I concentration does not guarantee that rhGH treatment is also effective on intermediate metabolism.",
author = "Paola Lucidi and Marco Lauteri and Stefano Laureti and Roberta Celleno and Stefania Santoni and Elena Volpi and Gabriella Angeletti and Fausto Santeusanio and {De Feo}, Pierpaolo",
year = "1998",
doi = "10.1210/jc.83.2.353",
language = "English (US)",
volume = "83",
pages = "353--357",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - A dose-response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults

AU - Lucidi, Paola

AU - Lauteri, Marco

AU - Laureti, Stefano

AU - Celleno, Roberta

AU - Santoni, Stefania

AU - Volpi, Elena

AU - Angeletti, Gabriella

AU - Santeusanio, Fausto

AU - De Feo, Pierpaolo

PY - 1998

Y1 - 1998

N2 - This study was designed to establish the lower dose of effective GH replacement therapy in severe GH-deficient (GHD) adults. Whole body protein and lipid kinetics were determined in six GHD men in the basal state (B) and after 1 week of treatment with placebo (PL) or 3.3 (GH3.3) or 2 (GH2) μg/kg·day recombinant human GH (rhGH). The rates of whole body proteolysis, oxidation, and synthesis were estimated by infusing [1-13C]leucine (prime, 1 mg/kg; infusion rate, 1 mg/kg·h); those of lipolysis (measured in four of the six patients) were estimated by infusing [1,1,2,3,3-D5]glycerol (prime, 1.8 μmol/kg; infusion rate, 0.06 μmol/kg·min). Serum insulin-like growth factor I (IGF-I) concentrations (picograms per mL; mean ± SE) similarly increased from the basal level (39 ± 7) after 3.3 (108 ± 18) or 2 (109 ± 24) μg/kg·day rhGH (P < 0.001 vs. basal), whereas they did not change with placebo (41 ± 8). Leucine Ra was unaffected by the treatments. GH3.3 reduced by 30% the rate of leucine oxidation (P = 0.0069 vs. basal) and increased by 11% nonoxidative leucine disposal (P = 0.0095 vs. basal) and by 21% glycerol Ra (0.0035 vs. basal); GH2 and placebo had no significant effect. In conclusion, 1) at least 3.3 μg/kg·day rhGH are required to increase whole body protein synthesis and lipolysis in male GHD adults; 2) 2 μg/kg·day rhGH normalize serum IGF-I concentrations, but do not modify protein and lipid metabolism; and 3) a normal serum IGF-I concentration does not guarantee that rhGH treatment is also effective on intermediate metabolism.

AB - This study was designed to establish the lower dose of effective GH replacement therapy in severe GH-deficient (GHD) adults. Whole body protein and lipid kinetics were determined in six GHD men in the basal state (B) and after 1 week of treatment with placebo (PL) or 3.3 (GH3.3) or 2 (GH2) μg/kg·day recombinant human GH (rhGH). The rates of whole body proteolysis, oxidation, and synthesis were estimated by infusing [1-13C]leucine (prime, 1 mg/kg; infusion rate, 1 mg/kg·h); those of lipolysis (measured in four of the six patients) were estimated by infusing [1,1,2,3,3-D5]glycerol (prime, 1.8 μmol/kg; infusion rate, 0.06 μmol/kg·min). Serum insulin-like growth factor I (IGF-I) concentrations (picograms per mL; mean ± SE) similarly increased from the basal level (39 ± 7) after 3.3 (108 ± 18) or 2 (109 ± 24) μg/kg·day rhGH (P < 0.001 vs. basal), whereas they did not change with placebo (41 ± 8). Leucine Ra was unaffected by the treatments. GH3.3 reduced by 30% the rate of leucine oxidation (P = 0.0069 vs. basal) and increased by 11% nonoxidative leucine disposal (P = 0.0095 vs. basal) and by 21% glycerol Ra (0.0035 vs. basal); GH2 and placebo had no significant effect. In conclusion, 1) at least 3.3 μg/kg·day rhGH are required to increase whole body protein synthesis and lipolysis in male GHD adults; 2) 2 μg/kg·day rhGH normalize serum IGF-I concentrations, but do not modify protein and lipid metabolism; and 3) a normal serum IGF-I concentration does not guarantee that rhGH treatment is also effective on intermediate metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0031765441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031765441&partnerID=8YFLogxK

U2 - 10.1210/jc.83.2.353

DO - 10.1210/jc.83.2.353

M3 - Article

VL - 83

SP - 353

EP - 357

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -